A look at the potential of semaglutide as adjunct treatment for patients with T2D and CKD and the results from the kidney outcomes FLOW trial.

Executed on:Mar 22, 2024 9:30 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: Massachussets General HospitalDirector of Dialysis Services and the Medical Director Emerita of the Renal and Pancreas Transplantation  at Massachusetts General Hospital; Professor of Medicine at Harvard Medical School.
Treats approximately 15 patients with IgA Nephropathy.
Research focus is on defining effective antirejection therapy directed against the T cell in both the efficacy of antithymocyte globulin (ATG) as well as the first human trials of the monoclonal antibody OKT3; Clinical focus on acute and chronic renal failure, Kidney transplants, UTIs and dialysis.

Interview Goal

This interview will focus on the potential of semaglutide and the headline results from the kidney outcomes trial FLOW, a trial measuring the effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.